BioSpace News Archive

The results showed that six weeks of treatment with LATUDA was associated with statistically significant and clinically meaningful improvement in a wide range of depressive symptoms compared to placebo.

It will provide a proposed AUD750,000 provisional funding to the Certara-Monash University Industry Fellowship Program over two years, with proposed matched funding of AUD750,000 coming from Certara®.

A conference call will be held at 5:00 p.m. Eastern Time to discuss those results.

The company announced its financial results for the six-months ended June 30, 2017, as approved by the Company’s Board of Directors on October 27, 2017.

Four out of six evaluable HRAS mutant HNSCC patients enrolled in the study achieved a confirmed partial response.

The Rare Genomics (RG) Institute is delighted to announce the launch of the 2018 BeHEARD (Helping Empower and Accelerate Research Discoveries) science challenge, a global competition that offers rare disease researchers, who traditionally have difficulty attracting funding, grants of cash and the latest life science innovations and technologies.

As the leading chemical supplier in the biochemical and pharmaceutical industry, on October 25, 2017, BOC Sciences announced to add an exclusive section for stem cell molecules into its product lines.

This dividend is payable on February 9, 2018 to all shareholders of record at the close of business on January 19, 2018.

Comments from the CEO: “During the third quarter of 2017, BioInvent has initiated preparations for a clinical trial with BI-1206 in combination with rituximab to investigate its potential as a treatment of relapsing, aggressive forms of Non-Hodgkin Lymphoma and indolent lymphomas.”